Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Int J Nephrol ; 2012: 580437, 2012.
Article in English | MEDLINE | ID: mdl-23119160

ABSTRACT

Androgens which are relatively cheap were used in the treatment of anaemia in dialysis patients before the advent of Erythropoietin (EPO). However, there are concerns about their efficacy and side effects. Aims. To examine the efficacy and harms of androgens for the treatment of anaemia of chronic kidney disease (CKD) compared to EPO. Settings and Design. A systematic review and meta-analysis using an a priori protocol. Methods and Materials. We searched several databases for randomized controlled trials using the key terms anaemia, chronic kidney disease, and androgens, without language restrictions. We also searched reference lists of relevant articles. Statistical Analysis Used. Data was analyzed using Review manger 5 software. We summarized treatment effects as relative risks and mean differences, with 95% confidence intervals using a random-effect model. We tested for heterogeneity with Chi(2) and the I(2) statistics. Results. We identified four eligible trials involving 114 participants, majority (83.33%) of whom were males, mostly over 50 years of age. The pooled difference in mean haemoglobin between the nandrolone and EPO arms at the end of the trials was -0.11 (CI -0.80 to 0.58) which is not statistically significant. Conclusions. This meta-analysis revealed no difference between nandrolone and EPO for the treatment of anaemia of CKD in men over 50 years. Therefore, nandrolone can be used for the treatment of anaemia of CKD in this category of patients, in resource-limited countries. However, further studies are needed to determine the long-term safety of nandrolone in men over 50 years old, as well as its effectiveness and safety in females in general, and males less than 50 years of age.

2.
Eur J Clin Microbiol Infect Dis ; 28(11): 1395-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19705174

ABSTRACT

We retrospectively evaluated 105 patients at the Mayo Clinic between 1970 and 2006 with native valve endocarditis who underwent acute valve surgery. The objective was to determine if outcomes differed based on whether they had received an antibiotic regimen recommended for native valve endocarditis or one for prosthetic valve endocarditis. Fifty-two patients had streptococcal and 53 had staphylococcal infections. Patients with each type of infection were divided into two groups: the first received postoperative monotherapy (with a beta-lactam or vancomycin), and the second received combination therapy (with an aminoglycoside for streptococcal infection, and gentamicin and/or rifampin for staphylococcal infection). The duration and types of antibiotics given pre- and postoperatively, valve cultures results, antibiotic-related adverse events, relapses, and mortality rates within 6 months of surgery were analyzed. Cure rates were similar regardless of the regimen administered. With the small number of patients in each group, a multicenter study with a larger cohort of patients is needed to better define optimal postoperative treatment regimens in this population.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Heart Valve Diseases/drug therapy , Adult , Aged , Aminoglycosides/therapeutic use , Drug Therapy, Combination , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/surgery , Female , Heart Valve Diseases/microbiology , Heart Valve Diseases/surgery , Humans , Male , Middle Aged , Retrospective Studies , Rifampin/therapeutic use , Staphylococcal Infections/drug therapy , Staphylococcal Infections/surgery , Streptococcal Infections/drug therapy , Streptococcal Infections/surgery , Treatment Outcome , Vancomycin/therapeutic use , beta-Lactams/therapeutic use
3.
Clin Microbiol Infect ; 15(4): 387-94, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19260876

ABSTRACT

Propionibacterium species rarely cause infective endocarditis. When identified in blood cultures, they may be inappropriately disregarded as skin flora contaminants. The purpose of this study was to characterize the clinical presentation and management of endocarditis due to Propionibacterium species. All cases of endocarditis due to Propionibacterium species that were treated at the Mayo Clinic, Rochester, USA were retrospectively reviewed, and the English language medical literature was searched for all previously published reports. Seventy cases, which included eight from the Mayo Clinic, were identified (clinical details were available for only 58 cases). The median age of patients was 52 years, and 90% were males. In 79% of the cases, the infection involved prosthetic material (39 prosthetic valves, one left ventricular Teflon patch, one mitral valve ring, one pulmonary artery prosthetic graft, three pacemakers, and one defibrillator). Blood cultures were positive in 62% of cases. All 22 cases with negative blood cultures were microbiologically confirmed by either positive valve tissue cultures (n = 21) or molecular methods (n = 1). Endocarditis was complicated by abscess formation in 36% of cases. The majority (81%) of patients underwent surgery, either for valve replacement and debridement of a cardiac abscess, or removal of an infected device. Crude in-hospital mortality was 16%. The median duration of postoperative antibiotic treatment was 42 days. Patients were commonly treated with a penicillin derivative alone or in combination with gentamicin. On the basis of the above data, it is recommended that infective endocarditis should be strongly suspected when Propionibacterium species are isolated from multiple blood cultures, particularly in the presence of a cardiovascular device.


Subject(s)
Endocarditis/microbiology , Gram-Positive Bacterial Infections/microbiology , Propionibacterium/isolation & purification , Prosthesis-Related Infections/microbiology , Abscess/microbiology , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Case Management , Endocarditis/diagnosis , Endocarditis/mortality , Endocarditis/therapy , Female , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/mortality , Gram-Positive Bacterial Infections/therapy , Humans , Male , Middle Aged , Prosthesis-Related Infections/diagnosis , Prosthesis-Related Infections/mortality , Prosthesis-Related Infections/therapy , Retrospective Studies , United States
4.
Heart ; 94(7): 892-6, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18308866

ABSTRACT

OBJECTIVE: The optimal timing of valve surgery in left-sided infective endocarditis (IE) is undefined. We aimed to examine the association between the timing of valve surgery after IE diagnosis and 6-month mortality among patients with left-sided IE. METHODS: We analysed data from a retrospective cohort of patients with left-sided IE who underwent valve surgery within 30 days of diagnosis at a tertiary centre. The association between time from IE diagnosis to surgery and all-cause 6-month mortality was assessed using Cox proportional hazards modelling after adjusting for the propensity score (to undergo surgery 0-11 days vs >11 days, median time, after IE diagnosis). RESULTS: Of 546 left-sided IE cases seen between 1980 and 1998, 129 (23.6%) underwent valve surgery within 30 days of diagnosis. The median time between IE diagnosis and surgery was 11 days (range 1-30). There were 35/129 (27.2%) deaths in the surgical group. Using Cox proportional hazards modelling, propensity score and longer time to surgery (in days) were associated with unadjusted HRs of (1.15, 95% CI 1.04 to 1.28, per 0.10 unit change, p = 0.009) and (0.93; 95% CI 0.88 to 0.99, per day, p = 0.03), respectively. In multivariate analysis, a longer time to surgery was associated with an adjusted HR (0.97; 95% CI 0.90 to 1.03). The propensity score and time from diagnosis to surgery had a correlation coefficient of r = -0.63, making multicollinearity an issue in the multivariable model. CONCLUSION: On univariate analysis, a longer time to surgery showed a significant protective effect for the outcome of mortality. After adjusting for the propensity to undergo surgery early versus late, a longer time to surgery was no longer significant but remained in the protective direction. Multicollinearity between the time to surgery and the propensity score may have hindered our ability to detect the independent effect of time to surgery.


Subject(s)
Endocarditis/surgery , Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation/methods , Adult , Aged , Aortic Valve/surgery , Endocarditis/pathology , Epidemiologic Methods , Female , Heart Valve Diseases/microbiology , Humans , Male , Middle Aged , Mitral Valve/surgery , Time Factors , Treatment Outcome
5.
Eur J Clin Microbiol Infect Dis ; 27(1): 53-63, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17938978

ABSTRACT

A recent meta-analysis, which included non-placebo open-labeled trials, showed that fluoroquinolone prophylaxis reduces mortality in neutropenic patients, whereas two recent large trials failed to show a similar benefit. Therefore, we performed a meta-analysis of randomized, blinded, placebo-controlled trials of fluoroquinolone prophylaxis in neutropenic patients. We searched several databases for relevant trials in any language. We used random effects models for pooling dichotomous data and assessed the between-study inconsistency with I (2). Two investigators independently assessed the eligibility and quality of the included trials. A total of 2,721 patients were randomized in eight eligible trials. Compared to the placebo, there was a statistically non-significant but consistent decrease in mortality with fluoroquinolone prophylaxis (4.5% vs. 3.9%, relative risk (RR) 0.76, 95% confidence interval (CI) 0.54, 1.08, p = 0.13, I (2) = 0%). Significant inconsistency, however, accompanied the pooled analysis of febrile episode (39% vs. 31%, RR 0.76, 95% CI 0.55, 1.03, p = 0.08, I (2) = 96.5%). To an extent, this inconsistency was explained in the subgroup analyses by the type of patient population studied and the type of fluoroquinolone used (p for interaction

Subject(s)
Antibiotic Prophylaxis/methods , Fluoroquinolones/therapeutic use , Neoplasms/complications , Neutropenia/complications , Opportunistic Infections/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Humans , Middle Aged , Neoplasms/therapy , Neutropenia/microbiology , Opportunistic Infections/blood , Opportunistic Infections/microbiology , Placebos , Randomized Controlled Trials as Topic , Treatment Outcome
6.
Int Orthop ; 32(1): 107-13, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17119962

ABSTRACT

We performed a meta-analysis of randomised controlled trials to investigate the effectiveness of surgical fusion for the treatment of chronic low back pain compared to non-surgical intervention. Several electronic databases (MEDLINE, EMBASE, CINAHL and Science Citation Index) were searched from 1966 to 2005. The meta-analysis comparison was based on the mean difference in Oswestry Disability Index (ODI) change from baseline to the specified follow-up of patients undergoing surgical versus non-surgical treatment. Of the 58 articles identified, three studies were eligible for primary analysis and one study for sensitivity analysis, with a total of 634 patients. The pooled mean difference in ODI between the surgical and non-surgical groups was in favour of surgery (mean difference of ODI: 4.13, 95%CI: -0.82 to 9.08, p = 0.10, I(2) = 44.4%). Surgical treatment was associated with a 16% pooled rate of early complication (95%CI: 12-20, I(2) = 0%). Surgical fusion for chronic low back pain favoured a marginal improvement in the ODI compared to non-surgical intervention. This difference in ODI was not statistically significant and is of minimal clinical importance. Surgery was found to be associated with a significant risk of complications. Therefore, the cumulative evidence at the present time does not support routine surgical fusion for the treatment of chronic low back pain.


Subject(s)
Low Back Pain/therapy , Orthopedic Procedures/methods , Spinal Fusion , Chronic Disease , Disabled Persons/classification , Humans , Low Back Pain/economics , Lumbar Vertebrae/surgery , Postoperative Complications , Randomized Controlled Trials as Topic , Treatment Outcome
7.
Eur J Clin Microbiol Infect Dis ; 27(2): 153-8, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18030505

ABSTRACT

Adenovirus is a frequent cause of mild self-limiting upper respiratory tract infection, gastroenteritis, and conjunctivitis in infants and young children. Fatal infections (severe pneumonia progressing to respiratory failure, septic shock and/or encephalitis) are rare among immunocompetent adults. We report a case of severe adenovirus pneumonia in a young immunocompetent male who presented with sudden onset respiratory distress that progressed rapidly to respiratory failure and made a successful recovery on supportive measures. Systematic review of the literature identified 14 cases of severe adenovirus pneumonia (defined as respiratory failure requiring ventilatory support at any point during the course of illness) in otherwise healthy immunocompetent adults both in epidemic and community settings. We describe the clinical characteristics, radiological features, and outcome of identified cases.


Subject(s)
Adenoviridae Infections/virology , Adenoviridae/isolation & purification , Pneumonia, Viral/virology , Adenoviridae Infections/complications , Adenoviridae Infections/therapy , Adolescent , Adult , Female , Humans , Male , Middle Aged , Pneumonia, Viral/complications , Pneumonia, Viral/therapy , Respiration, Artificial , Respiratory Insufficiency , Ventilators, Mechanical
8.
Eur J Clin Microbiol Infect Dis ; 25(6): 349-53, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16767481

ABSTRACT

Skin flora is an important source of microorganisms that cause infective endocarditis. While staphylococcal and beta-hemolytic streptococcal species are well-recognized components of skin flora that can cause infective endocarditis, other skin flora rarely produce endocardial infection. One species of Corynebacterium has received the most attention, Corynebacterium jeikeium. This bacterium, a gram-positive rod that is a strict aerobe, is known to cause mechanical prosthetic valve infection and vancomycin is generally required for treatment of this multidrug-resistant organism. Following treatment of an unusual case of bioprosthetic valve endocarditis due to C. jeikeium, a Medline search for English-language articles published from January 1966 to October 2004 was performed. Reports of C. jeikeium endocarditis cases with culture of either blood or cardiac surgery tissue samples positive for C. jeikeium and with clinical and echocardiographic findings of infective endocarditis were reviewed. Clinical data and results of diagnostic procedures were examined. All 38 patients with C. jeikeium endocarditis reported in the literature had at least one predisposing condition for the development of infective endocarditis. The majority of patients (74%) had involvement of a prosthetic heart valve. The mortality attributed to C. jeikeium endocarditis was 33% and was similar in patients who did and did not undergo valve replacement. This relatively high mortality rate mandates that clinicians be aware of this rare endocardial infection. C. jeikeium is a rare cause of endocarditis and it more commonly infects prosthetic valves. Careful scrutiny is required when C. jeikeium is isolated from a blood culture, particularly in patients with underlying prosthetic cardiac valves.


Subject(s)
Corynebacterium Infections/microbiology , Corynebacterium/classification , Endocarditis, Bacterial/microbiology , Aged, 80 and over , Corynebacterium Infections/mortality , Corynebacterium Infections/therapy , Endocarditis, Bacterial/mortality , Endocarditis, Bacterial/therapy , Humans , Male
9.
Bone Marrow Transplant ; 37(7): 677-86, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16489362

ABSTRACT

Hepatic veno-occlusive disease is a serious regimen-related toxicity in patients undergoing hematopoietic stem cell transplantation. We performed a systematic review and meta-analysis of the literature on the effect of anticoagulation in preventing veno-occlusive disease. Several databases and online journals were searched for randomized controlled trials and cohort studies. Twelve studies (2782 patients) were eligible. Anticoagulation prophylaxis was associated with a statistically nonsignificant decrease in risk of veno-occlusive disease (pooled relative risk (RR), 0.90; 95% confidence interval (CI), 0.62-1.29). Results of one of three randomized controlled trials may have been affected by delayed introduction of anticoagulation. A second trial enrolled patients who received conventional chemoradiotherapy for early-stage disease (RR, 0.18; 95% CI, 0.04-0.78). The third trial was a pilot study with a small sample size (RR, 0.74; 95% CI, 0.53-1.04). Significant heterogeneity and methodologic weaknesses preclude drawing a meaningful conclusion from the pooled analysis. Despite some limitations, results of two of three eligible randomized controlled trials suggest that prophylactic anticoagulation may help prevent veno-occlusive disease. However, a large randomized controlled trial is needed for confirmation. Additionally, in future studies, owing to the wide spectrum of severity of veno-occlusive disease, outcomes such as 100-day mortality should strongly be considered.


Subject(s)
Anticoagulants/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatic Veno-Occlusive Disease/prevention & control , Hepatic Veno-Occlusive Disease/therapy , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Cohort Studies , Databases as Topic , Hepatic Veno-Occlusive Disease/diagnosis , Humans , Meta-Analysis as Topic , Pilot Projects , Randomized Controlled Trials as Topic , Risk Factors , Treatment Outcome
10.
Eur J Clin Microbiol Infect Dis ; 24(9): 634-6, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16175357

ABSTRACT

Cytomegalovirus (CMV) cholangitis is a rare manifestation of CMV infection that has previously been described only in HIV-infected patients and solid-organ-transplant recipients. Reported here is a case of CMV cholangitis that occurred in a patient on chronic corticosteroid therapy who presented with recurrent hemobilia and biliary obstruction and was successfully treated with ganciclovir and cholecystostomy. A search of the medical literature revealed no previous case of this kind.


Subject(s)
Cholangitis/etiology , Cytomegalovirus Infections/etiology , Hemobilia/etiology , Adrenal Cortex Hormones/adverse effects , Antiviral Agents/therapeutic use , Cholangitis/drug therapy , Cholangitis/surgery , Cholecystostomy , Cytomegalovirus Infections/drug therapy , Ganciclovir/therapeutic use , Hemobilia/surgery , Humans , Hypereosinophilic Syndrome/complications , Hypereosinophilic Syndrome/drug therapy , Male , Middle Aged , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...